Similar Articles |
|
Chemistry World October 17, 2012 Maria Burke |
GSK pledge on trials transparency GlaxoSmithKline has announced a series of initiatives to make clinical trial data publically available that could set a precedent in an industry not known for its transparency. |
Chemistry World August 7, 2013 Emma Stoye |
AllTrials releases plan for clinical trial reporting The organizations behind AllTrials, a public campaign calling for detailed information on clinical trials to be publically available, have put together a detailed plan on how to achieve clinical trial reporting on a global scale. |
Chemistry World October 8, 2014 Phillip Broadwith |
EMA finalizes trial transparency rules The European Medicines Agency has finalized its policy for sharing data from clinical trials. |
Chemistry World September 5, 2014 Emma Stoye |
Servier to appear in adverts over lack of transparency European pharma group Servier Laboratories is to appear in adverts for breaching the Association of the British Pharma Industry code of practice by failing to publish clinical trial results. |
Chemistry World May 8, 2013 Phillip Broadwith |
Clinical trial data release blocked by companies Two pharmaceutical companies have been granted injunctions to prevent the European Medicines Agency from releasing clinical trial data about their drugs. |
Chemistry World February 4, 2014 Andy Extance |
J&J puts trial data in independent hands In a first-of-its-kind deal, Pharmaceutical firm Johnson & Johnson is making all of its drug trial data available via Yale University, US. |
Pharmaceutical Executive September 1, 2008 Melanie North |
Publish or Perish FDAAA means that companies need to register clinical trials; and not only for publication planning. |
Pharmaceutical Executive November 1, 2014 |
EMA -- a Pioneer Permanently At Bay Agency's plan for reporting clinical trial data has sparked strong reactions from health campaigners, industry, and patients. |
Pharmaceutical Executive October 1, 2005 Lisa Grimes |
Clear Road Ahead An industry standard for publicizing clinical-trial results is a ways off. But pharma's openness to more transparent procedures is moving things in the right direction. |
Chemistry World September 30, 2014 |
Transparency measures forced on pharma Previous misdemeanors are compelling the pharmaceutical industry to be more open with financial information and clinical data. |
Bio-IT World July 2005 Kevin Davies |
Trial Registries on Trial A group of influential editors from some of the world's boutique medical journals begin enforcing a new policy that would bar drug companies from publishing clinical trial data unless those trials are registered in a suitable public database. |
The Motley Fool December 8, 2004 Alyce Lomax |
Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days. |
Information Today July 2, 2013 |
Thomson Reuters Offers Clinical Trial Intelligence Solutions These solutions improve clinical trials, speed up product development and release, and help professionals strengthen portfolios and R&D strategy. |
Chemistry World September 17, 2013 Phillip Broadwith |
GSK criticized for trial data secrecy An Italian research institute has withdrawn from a public -- private partnership after quarrelling with GlaxoSmithKline about access to data from an antibiotic clinical trial being run by the institute. |
Information Today July 9, 2015 |
The BMJ Requires Patient-Level Data for Publication The BMJ is now applying its data-sharing policy to all clinical trials. |
Pharmaceutical Executive June 1, 2005 Joanna Breitstein |
Turn the Page Changes in ethics and expectations are driving the way pharma interacts with medical publishers. |
The Motley Fool June 21, 2004 Brian Gorman |
Clinical Trials Controversy The American Medical Association wants more transparency in clinical trials, a proposal that may leave drug companies and investors with mixed feelings. |
Chemistry World January 7, 2014 Angeli Mehta |
Flu drug stockpile may be worthless The case for spending hundreds of millions of pounds stockpiling antivirals for use in a flu pandemic is based on 'judgement rather than on evidence of their effectiveness', according to a parliamentary committee. |
The Motley Fool September 8, 2004 Charly Travers |
Will a Clinical Trial Database Help Investors? While this development is certainly good news for patients and physicians, the impact on investors may be minimal, depending upon the type of data that will be released. |
Bio-IT World April 2006 Mark D. Uehling |
Debating Clinical Registries and Databases The pharmaceutical industry has been forced by medical journal editors and Congress to make public more data about clinical trials. Registries are here, most people are used to them, and they're not going away. But can the industry do registries and databases better? |
Chemistry World November 27, 2012 Andrew Turley |
Roche and the Tamiflu data The Swiss pharma company has agreed to talk to external groups about full access to data for antiviral Tamiflu (oseltamivir) tablets, according to a letter published by the British Medical Journal. |
Pharmaceutical Executive March 1, 2014 Jill Wechsler |
Data disclosure, integrity challenge pharma Transparency initiatives are multiplying, affecting research, marketing and compliance. |
Managed Care July 2005 Martin Sipkoff |
Support Grows for Establishing National Clinical Trial Registry Stakeholders are pushing for a national clinical trial registry, and efforts by UnitedHealth Group are in the forefront. Medical journals are setting hard and fast rules. |
Reason October 2007 Ronald Bailey |
Is Industry-Funded Science Killing You? The overrated risks and underrated benefits of pharmaceutical research "conflicts of interest." |
Chemistry World July 3, 2014 Andy Extance |
EMA wrangles restrain trial data progress Tempers are being tested as the pharmaceutical industry's journey towards transparency on clinical trial data enters a critical phase. |
The Motley Fool November 13, 2009 Brian Orelli |
Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant. |
Chemistry World November 25, 2013 Phillip Broadwith |
Pfizer teams up with GSK in cancer drug trial Pfizer and GlaxoSmithKline have agreed to run a joint clinical trial to test a combination of Pfizer's candidate molecule palbociclib with GSK's approved drug Mekinist (trametinib) for advanced or metastatic melanoma. |
Managed Care September 2005 Arthur Lazarus |
Individual Wariness Needed To Spot Biased Drug Research Full and accurate disclosure of conflicts by researchers does not ensure the prevention of publication of articles that are misleading or otherwise biased. Impossible-to-enforce mandates won't work. Pharmacy directors and others must pose the right questions to the right people. |
The Motley Fool July 27, 2007 Tom Taulli |
A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth. |
Bio-IT World January 21, 2005 |
How IT Can Decrease Time-to-Market in Clinical Trials Pharma manufacturers can learn from their industrial counterparts: Integrating systems can accelerate product delivery. |
Bio-IT World August 13, 2002 Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
The Motley Fool October 12, 2010 Travis Hoium |
Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial. |
AskMen.com Richard Stevens |
Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process. |
The Motley Fool September 25, 2008 Brian Lawler |
Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors. |
Pharmaceutical Executive June 1, 2006 Jill Wechsler |
Washington Report: Promises to Keep Congress wants pharma to meet study commitments and disclose research results, but no one is giving FDA more resources to enforce its rules. |
Chemistry World July 25, 2006 Bea Perks |
Clinical Chaos Under Scrutiny Clinical trials of new drugs need to be tightened up, according to an expert group convened in the aftermath of UK trials that left six people fighting for their lives. |
Chemistry World November 27, 2012 Derek Lowe |
Full disclosure? I've been meaning to comment on all the recent calls for the drug industry to be more open with its clinical trial data. But it's hard for me to come up with anything more than 'I think it's a good idea!' |
The Motley Fool December 4, 2007 Brian Orelli |
An Early Gift to Drugmakers Drugmakers could be allowed to market for drugs' off-label indications. |
The Motley Fool October 26, 2006 Brian Lawler |
Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth. |
Bio-IT World March 10, 2003 Dawn Stover |
E-Recruitment: Trial by Wire Online databases are helping patients find clinical trials -- but e-recruitment is no panacea for participant shortages. |
Pharmaceutical Executive February 1, 2014 |
Will Europe's Regulatory Watchdog Come Of Age In 2014? The author looks at the growing pains of the European Medicine Agency as it faces key policy challenges of 2014. |
Pharmaceutical Executive November 1, 2013 Jill Wechsler |
Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise. |
Chemistry World November 12, 2013 Dinsa Sachan |
Rough patch for India's clinical trial industry The Indian clinical trial industry is beset by uncertainty. Campaigners have petitioned the courts claiming that drug companies are exploiting poor people and this has led to more than 100 trials being put on hold. |
Chemistry World January 30, 2007 Bea Perks |
BBC and GSK Battle Over Seroxat The UK pharmaceutical giant, which has spent the past few years fighting off accusations of risks associated with its market-leading anti-depressant, has rejected fresh claims that it improperly withheld medical trial information in the 1990s. |
Chemistry World March 4, 2013 Andy Extance |
UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries. |
Bio-IT World May 9, 2003 Mark D. Uehling |
Data Rapture? Electronic capture of data: Some say it unclogs the medieval clinical trials process. Others remain skeptical of software and put their trust in paper. |
Bio-IT World April 16, 2004 Mark Uehling |
PDAs and Clinical Trials PalmOne's director of healthcare sales explains why clinical trials are driving sales of handheld devices. |
Pharmaceutical Executive May 1, 2005 Sarah Houlton |
Global Report: Iron Fist The United Kingdom is hardening its stance on pharma industry issues. |
Bio-IT World April 2006 Kevin Davies |
Putting the IT in Clinical Trials A new report says that the clinical trials process must be reinvented to reverse the output decline of the pharmaceutical industry and meet the needs of its patients. That reinvention will be shaped by major advances in information technology. |
Bio-IT World February 2006 Mark D. Uehling |
Pharma's Mixed Response to Trials Database A late December New England Journal of Medicine article detailed Big Pharma's response to mandatory registration of clinical trials. Here are some highlights. |